DiaMedica Therapeutics Inc.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DIAMEDICA THERAPEUTICS INC. | ||
| Date: March 17, 2025 | By: | /s/ Rick Pauls |
|---|---|---|
| Rick Pauls | ||
| President and Chief Executive Officer | ||
POWER OF ATTORNEY
Each person whose signature appears below constitutes and appoints Rick Pauls and Scott Kellen, or either of them, as such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K and any documents related to this report and filed pursuant to the Securities Exchange Act of 1934, as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney shall be governed by and construed with the laws of the State of Minnesota and applicable U.S. federal securities laws.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Rick Pauls | President, Chief Executive Officer and Director | March 17, 2025 |
| Rick Pauls | (principal executive officer) | |
| /s/ Scott Kellen | Chief Financial Officer and Secretary | March 17, 2025 |
| Scott Kellen | (principal financial and accounting officer) | |
| /s/ James Parsons | Chairman of the Board | March 17, 2025 |
| James Parsons | ||
| /s/ Michael Giuffre, M.D. | Director | March 17, 2025 |
| Michael Giuffre, M.D. | ||
| /s/ Richard Kuntz, M.D. | Director | March 17, 2025 |
| Richard Kuntz, M.D. | ||
| /s/ Tanya N. Lewis | Director | March 17, 2025 |
| Tanya N. Lewis | ||
| /s/ Daniel O’Connor | Director | March 17, 2025 |
| Daniel O’Connor | ||
| /s/ Richard Pilnik | Director | March 17, 2025 |
| Richard Pilnik | ||
| /s/ Charles P. Semba, M.D. | Director | March 17, 2025 |
| Charles P. Semba, M.D. | ||
[page intentionally left blank]
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.